PubMed

Display Settings: Abstract

Full text links

J Clin Psychopharmacol. 2001 Aug;21(4):408-16.

An evaluation of risperidone drug interactions.

DeVane CL[1], Nemeroff CB.

Author information

Abstract

Risperidone, an atypical antipsychotic **drug**, is widely used in the treatment of psychoses associated with schizophrenia, Alzheimer's disease, and other psychiatric disorders. Polypharmacology is a necessary condition for the optimal treatment of many patients with comorbid psychiatric and medical illness. One concern raised by the widespread use of multiple concurrent pharmacotherapies is the potential for **drug-drug interactions** to adversely affect patient outcome. Accordingly, the biomedical literature was reviewed for reports of **drug interactions** involving **risperidone**, and the clinical significance of each report was evaluated. Additionally, the potential for **risperidone** to participate in **drug interactions** was evaluated by considering the **drug**'s pharmacokinetic properties. Controlled studies and case reports indicate that **risperidone** has a low potential for metabolic **drug interactions**. Drugs that inhibit cytochrome P450 (CYP) 2D6 or induce or inhibit CYP3A4 may alter **risperidone** plasma concentrations, but the clinical significance of such **interactions** seems to be minimal. Adherence to a few guidelines for the design of dosage regimens should limit the effect of **drug-drug interactions** on patient status and contribute to optimal pharmacotherapy with **risperidone**.

PMID: 11476125 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources

PubMed Commons

PubMed Commons home

0 comments

How to join PubMed Commons